# Essentiality of INH in TB Therapy

> **NCT01589497** · PHASE2 · COMPLETED · sponsor: **Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections** · enrollment: 69 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifampicin
- **DRUG:** Isoniazid
- **DRUG:** Pyrazinamide
- **DRUG:** Ethambutol
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT01589497
- **Lead sponsor:** Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-30
- **Primary completion:** 2016-01-28
- **Final completion:** 2016-02-10
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2018-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01589497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01589497, "Essentiality of INH in TB Therapy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01589497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*